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Background: The indications and extent of cervical lymph node dissection in papillary thyroid carcinoma (PTC) are
still being debated. The aim of this study was to analyze the patterns of cervical lymph node metastasis in the
lateral and central compartment and related factors and suggest the optimal extent of lateral and central neck
dissection for PTC patients with clinical lateral lymph node metastasis.
Methods: We retrospectively analyzed 72 patients with unilateral PTC who underwent therapeutic lateral neck
dissections with concomitant total thyroidectomy and central neck dissection between January 2001 and
December 2009.
Results: The 72 patients underwent 79 sides of therapeutic lateral neck dissection. The most frequent metastatic
level in the ipsilateral lateral compartment was level IV (75.0%), followed by level III (69.4%), level II (56.9%) and level
V (20.8%). Multiple level metastases were common (77.8%) and were correlated with tumor size (≥ 10 mm). The
central compartment lymph node metastasis rate was 87.5%, including 26.4% of contralateral central compartment
metastases.
Conclusion: In PTC patients with clinical lateral lymph node metastasis, the optimal extent of lateral and central
neck dissection should include levels II, III, IV and V as well as the bilateral central compartment.
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Papillary thyroid carcinoma (PTC) involves cervical
lymph nodes in 30-80% of patients. Cervical lymph node
metastasis in PTC has been found to be one of the most
significant factors for locoregional recurrence, and it also
has an adverse impact on survival, especially in older
patients [1-3]. Therefore, appropriate treatment of overt
and occult cervical lymph node metastasis acquires great
importance for improving survival and minimizing re-
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reproduction in any medium, provided the orPTC with lateral compartment lymph node metastasis
is considered more advanced than that with central
compartment lymph node metastasis only. Dissection of
the lateral compartments increases the frequency of
complications because of the greater surgical invasive-
ness. Prophylactic lateral neck dissection is not generally
recommended [4]. Because there is no evidence for the
clinical significance of prophylactic lateral neck dissec-
tion, there is no consensus on its application among sur-
geons worldwide, although some Japanese surgeons
recommend prophylactic lateral neck dissection for large
primary tumor or massive extrathyroidal extension [5,6].
Therapeutic lateral neck dissection should be performed
on patients who have PTC with clinically apparent cer-
vical lymph node metastasis detected on palpation ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lateral neck dissection remains controversial. Overall,
there is no evidence to prove which approach is most
appropriate for the management of lateral compartment
lymph node metastasis, although most specialists believe
that the berry-picking procedure should be avoided for
initial therapeutic lateral neck dissection [10].
Therapeutic or prophylactic central neck dissection is
usually performed simultaneously with therapeutic lat-
eral neck dissection because of the high rate of central
compartment lymph node metastasis. However, the ex-
tent of central neck dissection to be performed in clinic-
ally positive lateral compartment lymph node metastasis
is also not clearly established. Some authors insist on ip-
silateral central neck dissection, others on bilateral cen-
tral neck dissection [11,12].
The aim of this study was to analyze patterns of lateral
and central compartment lymph node metastasis and to
suggest the optimal surgical extent of neck dissection in
the lateral and central compartment for PTC patients
with clinical lateral compartment lymph node metastasis.
Methods
We retrospectively reviewed the clinical records of 72
patients with unilateral PTC who had undergone thera-
peutic lateral neck dissection with concomitant total thyr-
oidectomy and central neck dissection between January
2001 and December 2009. All patients were confirmed as
having lateral compartment lymph node metastasis by
postoperative pathology reports. We excluded cases with
bilateral PTC, recurrent cases or other types of thyroid
cancer. We also excluded patients who had no pathologic
lateral lymph node metastasis after therapeutic lateral
neck dissection or had undergone neck dissection for
other diseases. Written informed consent was obtained
from the patient for publication of this report and any ac-
companying images. The Institutional Review Board of
Hanyang University Hospital approved the study.
Physical examination, thyroid ultrasonography (US),
neck computed tomography (CT) and fine-needle aspir-
ation cytology were performed for preoperative evalu-
ation of the primary thyroid tumors and suspicious
cervical lymph nodes in the lateral and central compart-
ment. The criteria for metastases requiring US were as
follows: round shape (long/short ratio < 2), microcalcifi-
cation, cystic change, hyperechogenicity and heteroge-
neous inner structure [13]. The criteria for CT were as
follows: enhancement, heterogeneous, cystic or necrotic
change and round shape. The size criteria for both US
and CT were based on an upper limit of 15 mm for the
nodal diameter of the normal long axis in the cases of
jugulodiagastric and submandibular nodes and 10 mm
for all other cervical nodes except for level VI [14]. We
did not apply size criteria in the central compartment[15]. Neck US and serum thyroglobulin measurement
(TSH-stimulated or TSH-suppressed thyroglobulin)
were performed at 6- to 12-month intervals to detect re-
currence. Mean follow-up period was 46.6 ± 31.9 months
(range 11–118).
We did not perform prophylactic lateral neck dissec-
tion for PTC patients with clinically negative lateral
neck. Levels II to V were routinely dissected in the lat-
eral compartment. Level I was dissected only if there
were radiographic, cytopathologic, or intraoperative
findings suggestive of metastatic cancer. The dissected
lateral compartment lymph node specimens were classi-
fied according to neck nodal level (levels I, II, III, IV and
V). The central compartment lymph node specimens
were also labeled by the surgeon according to their loca-
tions using the definitions of the central compartment
and its subgroups in the recent consensus statement of
the American Thyroid Association (ATA), and they were
sent for permanent biopsy. The ipsilateral central com-
partment lymph node was defined as including pretra-
cheal, prelaryngeal, ipsilateral paratracheal lymph nodes,
and the contralateral central compartment lymph node
included the contralateral paratracheal lymph nodes.
SPSS version 15.0 software (SPSS, Inc.) was used for
statistical analysis. Fisher’s exact test was used to analyze
the relationship between various clinicopathologic fac-
tors and cervical lymph node metastasis and recurrence
(univariate analysis). Binary logistic regression analysis
was used for multivariate analysis. A P-value of less than
0.05 was taken as statistically significant.
Results
The characteristics of patients and tumors are listed in
Table 1. The study group comprised 51 women (70.8%)
and 21 men (29.2%). Mean age was 43.8 ± 14.2 years
(range 15–80 years).
Of 72 patients, a total of 79 sides of therapeutic lateral
neck dissections were performed. Therefore, ipsilateral lat-
eral neck dissection was performed in all patients and
contralateral lateral neck dissection in seven patients
(9.7%). All patients underwent lateral neck dissection in-
cluding levels II-V in the neck each. There was one patient
with suspicious metastatic lymph nodes at ipsilateral level
I, so modified radical neck dissection including levels I to
V was performed in this one (1.4%) patient.
All patients underwent therapeutic (32 cases, 44.4%)
or prophylactic (40 cases, 55.6%) bilateral central neck
dissection simultaneously with the lateral neck dissec-
tion based on imaging findings.
Among the 72 ipsilateral lateral necks, 75.0% of the
lymph node metastases were in level IV, 69.4% in level
III, 56.9% in level II and 20.8% in level V. There was no
metastasis in level I in the final pathologic report. In the
seven clinical contralateral lateral necks, the frequency
Table 1 Patient demographics and tumor characteristics
(n = 72)
Characteristics Number of patients (%)
Gender Male:female = 21 (29.2%):51 (70.8%)
Age 43.8 ± 14.2 years (range 15–80 years)
Size 21.8 ± 13.1 mm (range 4–65 mm)
Location of tumor
Upper third 18 (25%)
Lower two-thirds 54 (75%)
Multifocality of tumor 23 (31/9%)
Minimal extrathyroidal extension 50 (69.4%)
Maximal extrathyroidal extension 11 (15.3%)









Stage I 38 (52.8%)
Stage IVA 34 (47.2%)
Table 2 Statistical analysis of factors the related to








Age (45≤) 0.461 0.704
Stage 0.489 0.752
Multiplicity 0.363 0.050
Location of primary tumor
(upper third or lower two-thirds)
0.638 0.670
Size of primary tumor 0.047 0.049
Minimal extrathyroidal extension 0.483 0.288
Maximal extrathyroidal extension 0.203 0.052
Lymphovascular invasion 0.276 0.065
Central neck metastasis 0.317 0.391
No. of metastatic nodes at level VI (≥2) 0.155 0.190
Table 3 Statistical analysis of factors related to








Age (45≤) 0.563 0.908
Stage 0.386 0.568
Multiplicity 0.124 0.148
Location of primary tumor
(upper third or lower two-thirds)
0.575 0.873
Size of primary tumor 0.198 0.260
Minimal extrathyroidal extension 0.532 0.844
Maximal extrathyroidal extension 0.116 0.064
Lymphovascular invasion 0.107 0.129
Multiple level metastasis (≥2) 0.560 0.882
Ipsilateral central neck metastasis 0.035 0.038
No. of metastatic nodes in the
ipsilateral central compartment (≥2)
0.031 0.017
Keum et al. World Journal of Surgical Oncology 2012, 10:221 Page 3 of 6
http://www.wjso.com/content/10/1/221of lymph node metastases was five in levels IV and III
and three in level II.
The pattern of lateral compartment lymph node me-
tastasis was not significantly different according to pri-
mary tumor location (upper third versus lower two-
thirds of the thyroid gland).
Multiple level lymph node metastases in the lateral
compartment were found in 56 (77.8%) patients (6 levels
in 1 case, 5 levels in 2 cases, 4 levels in 6 cases, 3 levels
in 22 cases and 2 levels in 25 cases). Single level lateral
compartment lymph node metastasis occurred in 16
(22.2%) ipsilateral necks (9 cases in level IV, 4 cases in
level III and 3 cases in level II). The multiple level lymph
node metastases were associated with tumor size
(≥10 mm) in multivariate analysis (p = 0.049) (Table 2).
Seven patients who underwent therapeutic bilateral lat-
eral neck dissection had lymph node metastasis in both
sides of lateral compartment. No patients had only
contralateral lateral compartment lymph node metasta-
ses. Six of the seven patients with contralateral lateral
compartment lymph node metastases also had central
compartment lymph node metastases, including five
with bilateral central compartment lymph node metasta-
ses and one with ipsilateral central compartment metas-
tasis. The occurrence of clinical contralateral lateral
compartment lymph node metastasis was significantly
associated with contralateral central compartment lymph
node metastasis (p = 0.002).Central compartment (level VI) lymph node metasta-
sis occurred in 63 (87.5%) (bilateral 18 cases, unilateral
45 cases) patients. Contralateral central compartment
lymph node metastasis occurred in 19 (26.4%). One pa-
tient had only contralateral central compartment lymph
node metastasis without ipsilateral central compartment
metastasis. In multivariate analysis, contralateral central
compartment lymph node metastasis was significantly
associated with ipsilateral central neck metastasis and
two or more metastatic central compartment lymph
nodes (Table 3). Skip metastasis, defined as lateral
compartment lymph node metastasis without central
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eight (11.1%) patients. Skip metastasis was not corre-
lated with any clinicopathologic factor.
The mean number of lymph nodes removed was 27.8
± 14.39 (range 6–71) in the lateral compartment (8.53 ±
6.92, 7.29 ± 4.45, 8.22 ± 5.1 and 4.18 ± 4.31 in levels II,
III, IV and V, respectively) and 7.91 ± 6.11 (range 1–35)
in the central compartment.
Of the occult metastases in the ipsilateral lateral com-
partment, 42.2%, 47.3%, 64.5% and 23.6% were in levels
II, III, IV and V, respectively. The sensitivities of the
combination of US and CT for the detection of lateral
cervical lymph node metastasis were 74.1%, 82.4%,
70.7% and 29.4% in levels II, III, IV and V, respectively.
In the central compartment, the occult metastasis rate
was 77.8% on the ipsilateral side and 27.0% on the
contralateral side. The sensitivity of the combination of
US and CT was 51.7% in the ipsilateral central com-
partment and 19.0% in the contralateral central
compartment.
Recurrence occurred in seven (9.7%) patients: regional
recurrence in four, locoregional recurrence in two and
distant metastasis in one. Of the six patients with re-
gional recurrence, four had recurrence in the dissected
level (3 cases in level IV, 2 cases in level VI and 1 case in
level V) and two in the undissected contralateral lateral
neck. Recurrence was associated with stage in multivari-
ate analysis (p = 0.032).
Discussion
The pattern of lymphatic drainage of the thyroid is rela-
tively consistent, and the spread of lymph node metasta-
sis in PTC takes place in a stepwise fashion. Generally,
cervical lymph node metastasis in PTC involves the cen-
tral compartment first, followed by the ipsilateral lateral
compartment and then the contralateral lateral compart-
ment and mediastinal lymph node [16,17]. However,
sometimes skip metastasis to the lateral compartment,
bypassing the central compartment, has been reported
[18]. The results of this study showed the similar lymph-
atic drainage pattern of PTC; most of the patients with
lateral compartment metastasis also had central com-
partment metastasis, and patients with contralateral lat-
eral compartment metastasis also had ipsilateral lateral
compartment and contralateral central compartment
metastasis.
Although several authors have described the frequency
and pattern of lateral compartment lymph node metasta-
sis, the optimal extent of therapeutic lateral neck dissec-
tion for PTC remains unclear. The ATA guidelines
advocate compartment-oriented en bloc lateral neck dis-
section in patients with clinical lateral compartment
lymph node metastasis, but offer no recommendation
concerning which nodal levels should be dissected [4].A formal modified radical neck dissection including
levels I, II, III, IV and V is usually not necessary in PTC
patients with lateral compartment lymph node metasta-
ses because of the great rarity of metastatic nodes at
level I. We performed level I dissection only in one case
with clinically apparent lymph nodes in level I, and the
final pathology revealed no metastasis in level I in this
study.
Several authors have reported that PTC metastasis is
generally present at levels II through V in lateral com-
partment neck metastasis, with level III or IV nodes
consistently the most frequently involved, and compre-
hensive neck dissection including levels II to V is neces-
sary for complete clearance of lateral neck metastasis
[19-21]. However, there is a question of whether or not
to routinely dissect level V, considering the potential
morbidity associated with injury to the spinal accessory
nerve. Some authors raise objections to routine level V
dissection for PTC patients with lateral compartment
lymph node metastasis [22,23].
However, level V was found to be involved in a sub-
stantial proportion of cases in this study and previous
studies [19,20]. In addition, preoperative imaging includ-
ing US and CT was found to lack sensitivity for detect-
ing metastatic disease in level V [24]. In this study, there
was 20.8% level V metastasis on the ipsilateral side. The
sensitivity of the combination of US and CT in level V
was low (29.4%), and the occult lymph node metastasis
rate of level V was relatively high (23.6%). Usually level
V metastases are not found in isolation and instead are
always associated with disease at multiple levels [19]. In
this study, there was no case of single level V metastasis,
and metastasis to level V was associated with level III
metastasis in multivariate analysis (Table 4).
Given the evidence both for and against dissection of
level V in PTC, we suggest, based on our results, that
routine level V dissection is necessary, especially in PTC
with level III metastasis, because of the frequent multi-
level metastasis and the difficulty detecting level V
lymph node metastasis preoperatively by imaging stud-
ies. When including level V dissection in lateral neck
dissection, it is sensible to incorporate all areas of level
V because there is no clear anatomical boundary be-
tween levels VA and VB, although some authors insist
on elective dissection of only level VB, showing their
results that metastatic PTC was identified in 0% of VA
and 40% of VB [25]. In this study, we routinely dissected
level VA and VB when performing level V dissection;
however, we did not divide the surgical specimens into
levels VA ad VB. Level VA dissection can be done with
low morbidity and little additional time. There was no
injury of the spinal accessory nerve or severe shoulder
syndrome among patients who underwent level V dis-
section including levels VA and VB in this study.








Age (45≤) 0.744 0.529
Stage 1.0 0.150
Multiplicity 1.0 0.718
Location of primary tumor
(upper third or lower two-thirds)
0.450 0.344
Size of primary tumor 0.197 0.150
Minimal extrathyroidal extension 1.0 0.817
Maximal extrathyroidal extension 0.672 0.771
Lymphovascular invasion 0.338 0.279
Central neck metastasis 0.337 0.173
Multiple level metastasis (≥2) 0.108 0.054
No. of metastatic nodes in the
lateral compartment (≥5)
0.097 0.057
Contralateral lateral neck metastasis 1.0 0.845
Level II metastasis 1.0 0.861
Level III metastasis 0.048 0.043
Level IV metastasis 0.484 0.288
Level II or III metastasis 0.439 0.297
Level III or IV metastasis 0.337 0.173
Level II, III and IV metastasis 0.279 0.197
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some authors have also raised objections to routine level
IIB dissection, to minimize damage to the spinal
accessory nerve [25-27]. They recommended elective
dissection of level IIB only when IIA is involved in the
disease, because level IIB metastasis is usually accom-
panied by level IIA metastasis. In this study, we dis-
sected level IIA and IIB together. However, we did not
divide the level II specimens into level IIA and IIB in the
most of the patients. Hence, we cannot throw any light
on the issue of level IIB dissection. Further study involv-
ing separate sampling of level IIB lymph nodes is
needed.
The central compartment lymph node is the most
common site of metastasis in PTC, and most patients
with lateral compartment lymph node metastasis also
have central compartment lymph node metastasis
[11,12,18]. Therefore, central neck dissection should be
routinely performed during the initial operation when
lateral compartment lymph node metastasis is suspected,
regardless of whether central lymph node metastasis has
been detected. However, the extent of the central neck
dissection that should be performed in clinically positive
lateral compartment lymph node metastasis has not
been clearly established. Roh et al. recommendedipsilateral central neck dissection along with lateral neck
dissection because of the low rate of contralateral central
compartment lymph node metastasis (8.9%) [11]. How-
ever, Koo et al. insisted on bilateral central neck dissec-
tion due to the relatively high rate of occult contralateral
central lymph node metastasis (34.3%), especially in
multifocal primary tumors and when there is positive
lymph node involvement at all lateral neck levels [12]. In
the present study, the central compartment lymph node
metastasis rate was very high (87.5%), and the contralat-
eral central compartment lymph node metastasis rate
was also relatively high (26.4%). Contralateral central
compartment lymph node metastasis was significantly
correlated with ipsilateral central compartment metasta-
sis. The sensitivity of the combination of US and CT
was very low (19.0%) in the contralateral central com-
partment, and the rate of occult metastasis in the
contralateral central compartment was also relatively
high (27.0%). Based on the results of this study, we
recommend bilateral central neck dissection when
therapeutic lateral neck dissection is performed because
of the high rate of occult metastasis and the low sensitiv-
ity of imaging studies in the contralateral central
compartment.
In this study, of six cases with regional recurrences,
four occurred in the previously dissected level and only
two occurred in an undissected contralateral lateral
neck. Recurrence was more frequent in previously dis-
sected areas than in those that had not yet been dis-
sected, indicating that surgeons should take great care to
achieve complete resection to prevent recurrence in the
same area. The prognostic significance of persistence of
occult micrometastasis or recurrence in cervical lymph
nodes in PTC is still unknown. However, it might be
clear that the complete removal of cervical lymph node
metastases can prevent lymph node recurrence and reo-
peration of the recurrence.
Conclusion
In PTC patients with clinical lateral lymph node metas-
tasis, multiple level metastases in lateral compartment
and concomitant central compartment lymph node me-
tastasis were common. The optimal extent of lateral and
central neck dissection should include levels II, III, IV
and V as well as the bilateral central compartment.
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